Stockscreener 앱 받기
15.77
11.13%
1.58
시간 외 거래:
15.83
0.06
+0.38%
Tonix Pharmaceuticals Holding Corp 주식(TNXP)의 최신 뉴스
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tonix Pharmaceuticals says prescriptions for chronic pain drug top 4,200 since launch - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares - MarketBeat
Tonix Pharmaceuticals (TNXP) CEO adds 15,000 shares in open-market buy - Stock Titan
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 - GlobeNewswire
Tonix CEO to spotlight fibromyalgia and Lyme programs in Lisbon - Stock Titan
Tonix Pharmaceuticals Files 8-K Announcing Change in Independent Registered Public Accounting Firm - Minichart
Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings - MarketBeat
Auditor change at Tonix (NASDAQ: TNXP) after going concern warning - Stock Titan
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - The Manila Times
Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum (NASDAQ:TNXP) - Seeking Alpha
This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’ - MSN
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch - Sahm
Understanding Momentum Shifts in (TNXP) - Stock Traders Daily
Tonix Pharma earnings missed by $0.79, revenue topped estimates - Investing.com South Africa
Tonix Pharmaceuticals reports $13.1M product revenue, $124.0M net loss for FY2025 - TradingView
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharmaceuticals (TNXP) Reports Mixed Q4 Results with Reven - GuruFocus
[ARS] Tonix Pharmaceuticals Holding Corp. SEC Filing - Stock Titan
Tonix Pharmaceuticals Q4 Earnings Beat Expectations with Revenue Surge - Intellectia AI
Tonix (TNXP) Sees Transformational Year with FDA Approval and St - GuruFocus
Tonix Pharmaceuticals Wins FDA Approval for TONMYA in Fibromyalgia and Expands CNS, Immunology, and Rare Disease Pipeline - Minichart
Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Quarterly Earnings Results - MarketBeat
Tonix Pharmaceuticals Holding Corp. Announces Successful Launch of TONMYA™ for Fibromyalgia and Provides 2025 Financial Highlights - Quiver Quantitative
Tonix Pharmaceuticals Holding 2025 10-K — Revenue $13.1M, EPS (14.57) - TradingView
First new fibromyalgia drug in 15 years sees 4,200 Tonmya prescriptions - Stock Titan
Aug Chart Watch: What are the future prospects of Tonix Pharmaceuticals Holding CorpTrade Entry Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
TNXP: New fibromyalgia drug launch shows positive uptake; Lyme prevention antibody advances in pipeline - TradingView
Tonix presents fibromyalgia drug data at Poland conference By Investing.com - Investing.com South Africa
B2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured Conference - TradingView
TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) Approved by FDA for Fibromyalgia—Tonix Pharmaceuticals Presents Positive Phase 3 Data Showing Rapid Pain Relief and Favorable Benefit-Risk Profile - Minichart
Tonix Pharmaceuticals (TNXP) Highlights New Findings on Tonmya a - GuruFocus
Tonix Pharma Highlights Positive Phase 3 Fibromyalgia Data - TipRanks
Tonix presents fibromyalgia drug data at Poland conference - Investing.com
Tonix Pharmaceuticals presents Phase 3 post hoc data showing rapid, significant pain relief with TONMYA - TradingView
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia - The Manila Times
TONMYA fibromyalgia data show rapid pain relief, Tonix (NASDAQ: TNXP) - Stock Titan
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase - GlobeNewswire
Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday - MarketBeat
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting - The Manila Times
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting - The Manila Times
New fibromyalgia drug Tonmya cuts pain in 14-week trial - Stock Titan
Is Tonix Pharmaceuticals Holding Corp stock a hidden gem2026 Growth vs Value & High Win Rate Trade Tips - baoquankhu1.vn
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating - GlobeNewswire
Is Tonix Pharmaceuticals Holding Corp. stock safe for conservative investors2026 Sector Review & Real-Time Volume Triggers - Naître et grandir
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development - Sahm
TNXP: Tonix Pharmaceuticals Shares Promising Results from Clinical Studies - GuruFocus
TONMYA fibromyalgia tablet under tongue bypasses first-pass liver metabolism - Stock Titan
Tonix Pharmaceuticals Announces Publication of Clinical - GlobeNewswire
Tonix Pharmaceuticals: Tonmya launches for fibromyalgia as pipeline advances toward key 2027 milestones - TradingView
Tonix Pharmaceuticals moves to Nasdaq Global Select Market - Investing.com Australia
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting - The Manila Times
Tonix Pharmaceuticals to Present Poster on Tonmya at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting - Bitget
Tonix Pharmaceuticals Announces Uplisting From Nasdaq Capital Market to Nasdaq Global Select Market - 富途牛牛
Tonix Pharma Uplists to Nasdaq Global Select Market - TipRanks
Tonix Pharmaceuticals announces uplisting from Nasdaq Capital Market to Nasdaq Global Select Market - marketscreener.com
Tonix Pharmaceuticals Moves Listing to Nasdaq Global Select Market - marketscreener.com
Tonix Pharmaceuticals (TNXP) Moves to Nasdaq Global Select Marke - GuruFocus
Tonix Pharmaceuticals Uplisted to Nasdaq Global Select Market, Enhancing Visibility and Growth Potential - Quiver Quantitative
Tonix Pharmaceuticals moves to Nasdaq Global Select Market By Investing.com - Investing.com UK
Tonix Pharmaceuticals (NASDAQ: TNXP) uplists to Nasdaq Global Select tier - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):